# AMED

AMED is a Government Agency based in Tokyo, Japan.

## Overview

- **Organization type:** Government Agency
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** Tokyo, Japan
- **Founded:** 2015
- **Assets under management:** Undisclosed
- **Website:** amed.go.jp
- **LinkedIn:** https://www.linkedin.com/company/japan-agency-for-medical-research-and-development

## Regulatory record

- **Reports private funds:** No

## About

Japan Agency for Medical Research and Development conducts research and development in medicine, from basic research to clinical trials. It oversees projects in various stages of development. The agency is responsible for promoting integrated research and development in the field of medicine.

## Sectors

- Healthcare Services
- Digital Health
- AI/ML

## People

- Mishima Kazuo — President

## Questions

### Who runs investment decisions at AMED?

President Mishima Kazuo oversees AMED's strategic allocation of its $1.25 billion annual budget. Programmatic funding decisions are guided by agency-wide review committees and scientific advisory panels composed of external experts, convened under AMED's Department of Research and Development Promotion. Major grants are peer-reviewed, with final authority resting with senior agency leadership.

### How does AMED source proprietary deal flow?

AMED does not source proprietary deal flow in the investor sense, but designs directed funding calls in areas of national strategic interest such as regenerative medicine, genomic medicine, and pandemic preparedness. The agency also draws on the research pipelines of Japan's leading universities and national research institutes — University of Tokyo, Kyoto University, RIKEN — whose proposals flow into AMED's integrated grant management system.

### Does AMED participate in fund commitments or only direct grants?

AMED operates almost entirely through direct grants, contracts, and consortia funding. It does not operate as a limited partner in venture capital funds, but its programs frequently co-fund projects alongside pharmaceutical companies and medical device manufacturers under formal collaboration agreements.

### What investment stages does AMED typically target?

AMED covers the full translational arc from preclinical proof-of-concept through Phase II clinical trials. Its programs are segmented by translational stage: basic science with clinical intent (AMED-CREST), applied translational projects, and clinical research trial enabling. It generally does not fund late-stage Phase III regulatory trials or commercial manufacturing.

### How is AMED related to global counterparts like the NIH?

AMED was explicitly modeled in part on the NIH, but operates on a smaller scale and with a tighter focus on translational, rather than broad basic, science. It has formal memoranda of cooperation with the NIH, the UK's Medical Research Council, and Canada's CIHR, and funds Japanese participation in international collaborative programs.

### Where does AMED's budget come from?

AMED's approximately $1.25 billion annual budget is appropriated by the Japanese government and draws from multiple ministries. This consolidation is AMED's core structural innovation — before 2015, similar funding was dispersed across MEXT, MHLW, and METI without coordination.

## Related profiles

- [Absolute Sports](https://altss.com/profile/absolute-sports-private-limited)
- [Greenbacker Capital Management](https://altss.com/profile/greenbacker-capital-management)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/japan-agency-for-medical-research-and-development

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology